COVID-19 Vaccines

Phase 1Vaccine

UUniversity of British Columbia

COVID-19 Vaccines is one of 97 small molecule programs targeting Liver Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver DiseaseActive, not recruiting

COVID-19Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Aimovig

Amgen

Preclinical

1 3

Calciferol

Activella

Nitrostat

VViatris Specialty LLC

Preclinical

1 6

Statins

Sanofi

Preclinical

1 7

Achromycin V

WWyeth-Lederle Vaccines

Glucocorticoid

1 9

Singulair

AstraZeneca

Preclinical

1 10

Rayaldee

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

COVID-19

NCT07416539

Clinical

Trials by Indication[1]

COVID-199 trials

The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes

Unknown status·MMebo Research, Inc.··NCT04832932·2,000 enrolled

COVID-19 Vaccine Effectiveness Among Health Workers in Georgia

Unknown status·NNational Center for Disease control and Public Health··NCT04868448·1,600 enrolled

Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians

Unknown status·—··NCT04706143·100 enrolled

Show 6 more trials

National Project on Vaccines, COVID-19 and Frail Patients

Completed·AAzienda USL Reggio Emilia - IRCCS··NCT04848493·747 enrolled

Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Unknown status·MMinistry of Public Health, Argentina·Phase 2·NCT04988048·1,760 enrolled

Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia

Completed·UUniversidad Nacional de Colombia··NCT04887246·4,078 enrolled

Genomics and COVID-19 Vaccine Adverse Events

Recruiting·UUniversity of British Columbia··NCT05212792·6,325 enrolled

Real-world Evidence of COVID-19 Vaccines Effectiveness

Terminated·IIvan S Moiseev··NCT04981405·182 enrolled

A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults

Active, not recruiting·RRokote Laboratories Finland Oy·Phase 1·NCT07416539·20 enrolled

Liver Disease1 trial

COVID-19 Vaccines in Patients With Chronic Liver Disease

Unknown status·—·N/A·NCT05017805·300 enrolled

Vaccination1 trial

App-based Symptom Tracking After Corona Vaccination (CoCoV)

Unknown status·UUniversity of Ulm··NCT04686409·500 enrolled

Immunization1 trial

Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.

Completed·HHospital Clinica Nova··NCT05228912·1,870 enrolled

Anaphylactic Reaction1 trial

Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05028257·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for COVID-19 Vaccines. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — COVID-19 Vaccines compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for COVID-19 Vaccines. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: UUniversity of British Columbia

COVID-19 Vaccines

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

COVID-199 trials

Liver Disease1 trial

Vaccination1 trial

Immunization1 trial

Anaphylactic Reaction1 trial

References

Drug Info

Quick Facts

Related News